Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
cell-based therapies
chronic diseases |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Robert_Langer
gptkb:Daniel_Anderson gptkb:Omid_Veiseh |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sigilon Therapeutics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableContributor |
gptkb:diabetes
gptkb:hemophilia_A lysosomal diseases |
| gptkbp:notableProduct |
gptkb:Shielded_Living_Therapeutics_platform
|
| gptkbp:stockSymbol |
gptkb:SGTX
|
| gptkbp:website |
https://www.sigilon.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:SGTX
|
| gptkbp:bfsLayer |
6
|